Ruth Gimeno, Ph.D., is Group Vice President at Eli Lilly and Company, leading cardiometabolic research and early clinical development across diabetes, obesity, cardiorenal diseases, and women's health. Under her leadership, Lilly has advanced a broad portfolio spanning obesity — with molecules such as tirzepatide, orforglipron, retatrutide, and eloralintide — as well as programs in diabetes and cardiovascular disease. Before joining Lilly in 2011, she held roles at Millennium Pharmaceuticals, Wyeth, and Pfizer. She trained in medicine at Julius-Maximilians-University in Würzburg, Germany, and earned her Ph.D. in biology from MIT.